英語ページ

Publications 2025

  1. Asano D, Kudo Y, Kobayashi S, Abe T, Ohuchida K, Akahoshi K, Wakabayashi G, Shimizu K, Mun M, Iwata H, Takenaka A, Habuchi T, Tanabe M, Yoshizumi T, Ban D, Ikeda N, Eto M, Kitagawa Y, Nakamura M. Anatomy on the Border Expert Consensus Meeting: Current Status and Future Perspectives of Three-Dimensional Image Reconstruction and Immersive Technologies in Liver Surgery. Asian J Endosc Surg 18:e70182, 2025.
  2. Bi K, Kashima S, Camp SY, Meli K, Saad E, Titchen BM, Labaki C, Bakouny Z, Pimenta EM, Park J, Shannon E, Fu J, Xirenayi S, Horst J, Lum L, Ishizuka JJ, Choueiri TK, Braun DA, Van Allen EM. Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma. Immunity 11:2814-2829.e9, 2025.
  3. Fujita N, Matsushita Y, Kojima T, Bando Y, Osawa T, Sazuka T, Goto K, Numakura K, Yamana K, Kandori S, Kawasaki Y, Kato T, Miyake M, Fujita K, Ueda K, Tanaka H, Tomida R, Kitamura H, Miyake H, Hatakeyama S; Japanese Urological Oncology Group. Impact of Impaired Renal Function on the Efficacy and Safety of Second-Line Tyrosine Kinase Inhibitor Therapy After First-Line Immuno-Oncology Combination Therapy in Metastatic Renal Cell Carcinoma: A Japanese Multicenter Retrospective Study. Int J Urol 32:1506-1517, 2025.
  4. Fukushima T, Numakura K, Shinohara M, Kawashima Y, Sekine Y, Mori K, Kobayashi M, Asanuma H, Ichiyama T, Sakurai H, Ozaki K, Fujita N, Okamoto T, Yamamoto H, Yoneyama T, Sato S, Habuchi T, Ohyama C, Hatakeyama S. Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma. Sci Rep 18:26127, 2025.
  5. Hamaya T, Matsuura T, Saito M, Nishida H, Maita S, Murakami R, Ito A, Kodama H, Tomita H, Saitoh H, Tsuchiya N, Habuchi T, Obara W, Ohyama C, Hatakeyama S. Benefits of Preemptive Living Kidney Transplantation: Reduced Rates of Cerebro-Cardiovascular Events and Neoplasm Development. Int J Urol 32:1843-1850, 2025.
  6. Hara S, Fukuokaya W, Miki J, Taoka R, Saito R, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kimura T; Japan Urological Oncology Group. Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy. Int J Urol 32:544-552, 2025.
  7. Hatakeyama S, Fujita N, Kobayashi M, Kandori S, Ikarashi D, Fukuhara H, Sato T, Myoen S, Uemura M, Inoue T, Oikawa M, Kaiho Y, Miyazaki J, Kojima Y, Adachi H, Ito A, Tsuchiya N, Obara W, Nishiyama H, Habuchi T, Ohyama C. Trends in the use and efficacy of adjuvant immunotherapy in muscle-invasive urothelial carcinoma. Sci Rep 12:25247, 2025.
  8. Hatakeyama S, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, Kawahara T, Matsuda A, Kawai T, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga KI, Yamaguchi N, Taguchi M, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Ohyama C; Japanese Urological Oncology Group. Effects of the Number of Neoadjuvant Cycles and Addition of Adjuvant Chemotherapy on the Prognosis of Muscle-Invasive Bladder Cancer Treated With Radical Cystectomy. Cancer Med 14:e70782, 2025.
  9. Hirata M, Tsukita K, Shindo T, Yagi S, Ito T, Tanaka S, Fujimoto R, Kayawake H, Nakamura K, Fujiyama N, Saito M, Yurugi K, Hishida R, Kato A, Kawaguchi A, Habuchi T, Kobayashi T, Date H, Hatano E. Cross-organ hierarchy of HLA molecular mismatches in donor-specific antibody development in solid organ transplantations. Cell Rep Med 17:102153, 2025.
  10. Huang M, Narita S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Koizumi A, Nara T, Numakura K, Saito M, Nanjo H, Ikezoe T, Habuchi T. IGFBP2 alteration contributes to prostate cancer progression by modulating prostate stroma activation. Cell Commun Signal 2:408, 2025.
  11. Huang M, Narita S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Koizumi A, Nara T, Numakura K, Saito M, Nanjo H, Ikezoe T, Habuchi T. Inhibition of Fatty Acid-Binding Protein 4 Limits High-Fat-Diet-Associated Prostate Tumorigenesis and Progression in TRAMP Mice. Int J Mol Sci 31:10621, 2025.
  12. Ichinose J, Itoh S, Narita S, Asano D, Kudo Y, Abe T, Ohuchida K, Akahoshi K, Wakabayashi G, Shimizu K, Iwata H, Takenaka A, Tanabe M, Ikeda N, Eto M, Nakamura M, Kitagawa Y, Yoshizumi T, Habuchi T, Mun M. Consensus Meeting of Anatomy on the Border, Appropriate Use and Precautions for ICG in Liver, Lung, and Renal Surgery. Asian J Endosc Surg 18:e70175, 2025.
  13. Ishii N, Sekine Y, Shinohara M, Kawashima Y, Mori K, Kobayashi M, Numakura K, Mikami J, Fujita N, Okamoto T, Yoneyama T, Tabata R, Sato S, Habuchi T, Ohyama C, Hatakeyama S. Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study. Cancer Med 14:e71241, 2025.
  14. Ito T, Ito M, Aida N, Kurihara K, Terao A, Watarai Y, Saito M, Kaku K, Ishii D, Sekiguchi S, Yoneda T, Unagami K, Tasaki M, Iwamoto H, Araki M, Takahashi K, Yamanaka K, Sugimoto M, Nishikawa K, Seto C, Muramatsu M, Asai T, Iwami D, Yamada Y, Yamanaga S, Komatsu T, Miura M, Nohara T, Maruyama M, Miyauchi Y, Tanaka T, Nakamura M, Hotta K, Kenmochi T. Potential of Kidney Exchange Programs (KEPs) in Japan for Donor-Specific Antibody-Positive Kidney Transplants: A Questionnaire Survey on KEPs and a Multi-Institutional Study Conducting Virtual Cross-Matching Simulations. J Clin Med 29:6122, 2025.
  15. Jikuya R, Fukagawa A, Ito D, Ishihara H, Takemura K, Kashima S, Kato T, Urabe F; Japanese Young Urologist Basic Research Collaboration. Translational Research Bridging Basic and Clinical Insights in Renal Cell Carcinoma: A Collaborative Review and Future Directions. Int J Urol 32:932-943, 2025.
  16. Jikuya R, Johnson TA, Muraoka E, Noguchi G, Maekawa S, Obara W, Numakura K, Habuchi T, Maejima K, Sasagawa S, Kanazashi Y, Lee H, Song WJ, Sasagawa H, Mitome T, Ohtake S, Kawaura S, Iribe Y, Aomori K, Nagasaka H, Tatenuma T, Ueno D, Komeya M, Ito H, Ito Y, Muraoka K, Kawahara T, Furuya M, Kato I, Hamanoue H, Nishiyama A, Tamura T, Baba M, Suda T, Kodama T, Ogawa T, Uemura H, Yao M, Tsuzuki T, Nagashima Y, Miura Y, Kimura G, Imoto S, Momozawa Y, Fujii S, Makiyama K, Hasegawa T, Shuch BM, Ricketts CJ, Schmidt LS, Linehan WM, Nakagawa H, Hasumi H. Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers. Nat Commun 24:10340, 2025.
  17. Kikuchi H, Osawa T, Matsushita Y, Kojima T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Ueda K, Tanaka H, Kurahashi T, Bando Y, Kimura T, Nishiyama N, Kato T, Hara H, Ito Y, Kitamura H, Miyake H, Shinohara N. Validation of five Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for s treated with axitinib beyond first-line nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma: a Japanese multicenter retrospective study. Jpn J Clin Oncol 26:531-538, 2025.
  18. Kikuta M, Naito S, Osawa T, Numakura K, Narisawa T, Takai Y, Yagi M, Sekine Y, Tokairin O, Shinohara N, Habuchi T, Tsuchiya N. Real-world short-term outcomes and treatment regimen comparisons in patients with metastatic renal cell carcinoma treated with first-line immune combinations. BMC Cancer 22:117, 2025.
  19. Kimura K, Watanabe K, Kobayashi M, Okubo K, Sato H, Narita S, Wada Y, Kumagai S, Sato K, Fukuda S, Yoshida T, Kodama S, Saruta Y, Abe R, Shimodaira Y, Matsuhashi T, Arita J, Mori N, Nanjo H, Habuchi T, Iijima K. Fournier's Gangrene Following Hydrogel Spacer-Related Rectal Ulcer and Fistula in a Patient Undergoing Radiation Therapy for Prostate Cancer: A Case Report. Intern Med, 2025.
  20. Kobayashi S, Asano D, Kudo Y, Narita S, Morizane S, Abe T, Ohuchida K, Habuchi T, Takenaka A, Wakabayashi G, Yoshizumi T, Akahoshi K, Ikeda N, Tanabe M, Nakamura M, Kitagawa Y, Eto M. Clinical Practice and Survey of Three-Dimensional Images, Virtual Reality, Augmented Reality and Mixed Reality for Robotic-Assisted Surgery in Urology-"Anatomy on the Border" Expert Consensus Meeting. Asian J Endosc Surg 18:e70189, 2025.
  21. Miyauchi T, Narita S, Saiki Y, Kudo-Asabe Y, Horii A, Fukushige S, Habuchi T, Nanjo H, Goto A. Association between NLRP3 Inflammasome and Tumor-Node-Metastasis Staging in Prostate Cancer: Immunohistochemical Studies of Prostate Needle Biopsy and Radical Prostatectomy Specimens. Tohoku J Exp Med 7:203-213, 2025.
  22. Mori K, Numakura K, Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Yamana K, Kandori S, Kimura T, Nishiyama N, Bando Y, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Kitamura H, Miyake H, Habuchi T. Primary resistance to nivolumab plus ipilimumab therapy affects second-line treatment outcomes in patients with metastatic renal cell carcinoma. Cancer Sci 116:444-452, 2025.
  23. Morizane S, Kobayashi S, Narita S, Fujii K, Abe T, Ohuchida K, Eto M, Habuchi T, Eguchi T, Nakamura M, Kitagawa Y, Takenaka A. Current Practices for Preventing Inguinal Hernia During Radical Prostatectomy: Findings From the "Anatomy on the Border" Consensus Survey by the Japan Society for Endoscopic Surgery. Asian J Endosc Surg 18:e70185, 2025.
  24. Narita S, Ichinose J, Itoh S, Kobayashi S, Morizane S, Asano D, Kudo Y, Abe T, Ohuchida K, Akahoshi K, Wakabayashi G, Shimizu K, Iwata H, Takenaka A, Tanabe M, Eto M, Ikeda N, Nakamura M, Kitagawa Y, Yoshizumi T, Mun M, Habuchi T. Details and Updates From the Consensus Meeting on Anatomical Borders for ICG Usage in Urological Laparoscopic and Robotic Kidney Surgery. Asian J Endosc Surg 18:e70184, 2025.
  25. Narita S, Yanagisawa T, Hatakeyama S, Hata K, Fujita K, Ueda T, Tanaka T, Maita S, Chiba S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Numakura K, Saito M, Takayama K, Okane K, Ishida T, Horikawa Y, Kumazawa T, Shimoda J, Iwabuchi I, Suzuki T, Ukimura O, Kimura T, Ohyama C, Nomura K, Habuchi T. Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy. Prostate 85:73-81, 2025.
  26. Nishimoto K, Kimura G, Sazuka T, Hamamoto S, Nozawa M, Numakura K, Mizokami A, Kondo T, Naito S, Abe T, Ohba K, Nagata M, Onodera S, Ito H, Uemura H. The Effectiveness and Safety Profile of Nivolumab-Plus-Ipilimumab in Previously Untreated Japanese Patients With Advanced or Metastatic Renal Cell Carcinoma (J-ENCORE Study). Int J Urol 32:961-972, 2025.
  27. Ozaki K, Yamamoto H, Sekine Y, Horiguchi H, Hosogoe S, Mikami J, Fujita N, Tokui N, Okita K, Okamoto T, Mori K, Kobayashi M, Numakura K, Yoneyama T, Tabata R, Sato S, Habuchi T, Ohyama C, Hatakeyama S. Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study. Int J Urol 32:679-685, 2025.
  28. Park SH, Chang YH, Lee JL, Choueiri TK, Kimura G, Chung J, Masumori N, Nishimura K, Kato M, Kato H, Numakura K, Chang CH, Anai S, Tsunemori H, Chen CH, Lin J, Elfiky A, Burgents JE, Kitamura H. Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study. Cancer Res Treat, 2025.
  29. Quijano E, Martinez-Saucedo D, Ianniello Z, Pinto-Medici N, Rackear M, Chen H, Lola-Pereira L, Liu Y, Hegan D, Shan X, Tseng R, Yugawa D, Chowdhury S, Khang M, Singh JP, Abdullah R, Azhir P, Kashima S, Woods WS, Gosstola N, Turner BC, Squinto S, Ludwig DL, Bindra RS, Robert ME, Braun DA, Perez Pinera P, Saltzman WM, Escobar-Hoyos LF, Glazer PM. Systemic administration of an RNA binding and cell-penetrating antibody targets therapeutic RNA to multiple mouse models of cancer. Sci Transl Med 17:eadk1868, 2025.
  30. Saito R, Taoka R, Miki J, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Sazuka T, Kato M, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kinoshita H; Japan Urological Oncology Group. Efficacy of cisplatin-based neoadjuvant chemotherapy and risk factors for residual extravesical disease in muscle-invasive bladder cancer: insights from a nationwide cohort. Int J Clin Oncol 30:2106-2117, 2025.
  31. Sazuka T, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Sawada A, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Ichikawa T; Japan Urological Oncology Group. Impact of lymph-node dissection during radical cystectomy for non-muscle-invasive bladder cancer: Japanese multicenter retrospective study. Int J Clin Oncol 30:1417-1425, 2025.
  32. Takahashi M, Matsushita Y, Kojima T, Osawa T, Sazuka T, Hatakeyama S, Goto K, Numakura K, Yamana K, Kandori S, Fujita K, Ueda K, Tanaka H, Tomida R, Kurahashi T, Bando Y, Kimura T, Nishiyama N, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Kawasaki Y, Kato T, Tatarano S, Masui K, Nakamura E, Kaneko T, Miyake M, Kitano G, Motoshima T, Shiraishi Y, Kira S, Murashima T, Hara H, Matsumura M, Kitamura H, Miyake H, Furukawa J; Japanese Urological Oncology Group. Effectiveness and Safety of Second-line Tyrosine Kinase Inhibitors After Discontinuation of First-line Immune-oncology Combination Therapy Because of Adverse Events in the Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 23:102322, 2025.
  33. Takamori H, Goto T, Kashima S, Yoshino T, Ogata T, Aizawa R, Nakamura K, Sano T, Sawada A, Akamatsu S, Yamasaki T, Inoue T, Mizowaki T, Ogawa O, Kobayashi T. The real prevalence and clinical courses of non-metastatic castration-resistant prostate cancer: a retrospective single-institutional study. Jpn J Clin Oncol 6:428-434, 2025.
  34. Takehara T, Nishida H, Ichikawa K, Nawano T, Takai S, Fukuhara H, Matsuura T, Maita S, Saito M, Murakami R, Hatakeyama S, Obara W, Saitoh H, Ohyama C, Habuchi T, Watanabe M, Tsuchiya N. Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study. Clin Exp Nephrol 29:359-367, 2025.
  35. Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group. Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer. Int J Clin Oncol 30:551-558, 2025.
  36. Tashiro K, Mori K, Shiota M, Fukuokaya W, Takamatsu D, Matsui Y, Kato M, Saito R, Yokomizo A, Tsutsumi M, Yamamoto Y, Edamura K, Miyake M, Morizane S, Yoshino T, Matsumoto R, Narita S, Kitamura H, Eto M, Kimura T; Japanese Urological Oncology Group. Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy. Int J Urol 32:1386-1392, 2025.
  37. Urabe F, Hatakeyama S, Yanagisawa T, Narita S, Muramoto K, Katsumi K, Takahashi H, Fukuokaya W, Mori K, Tashiro K, Iwatani K, Shimomura T, Miki J, Habuchi T, Kimura T; JHA Collaborative Group. Clinical significance of PSA dynamics in castration-sensitive prostate cancer treated with ARSI doublet therapy: A multicenter study. Urol Oncol 43:271.e9-271.e18, 2025.
  38. Xu W, Birch G, Meliki A, Moritz V, Bharadwaj M, Schindler NR, Labaki C, Saliby RM, Dinh K, Horst JT, Sun M, Kashima S, Hugaboom M, Dighe A, Machaalani M, Lee GM, Hurwitz M, McGregor BA, Hirsch MS, Shukla SA, McDermott DF, Signoretti S, Romee R, Choueiri TK, Braun DA. Progressive natural killer cell dysfunction in advanced-stage clear-cell renal cell carcinoma and association with clinical outcomes. ESMO Open 10:104105, 2025.
  39. Yamamoto R, Numakura K, Aoyama Y, Okubo K, Sasagawa H, Mori K, Sekine Y, Sato H, Kobayashi M, Saito M, Narita S, Habuchi T. Reassessment of T1a cutoff for kidney cancer in the robotic era. J Robot Surg 12:595, 2025.
  40. Yamamoto R, Saito M, Matsuura T, Hatakeyama S, Nishida H, Maita S, Furihata K, Kajiwara C, Mori M, Aoyama Y, Ito A, Murakami R, Tomita H, Saitoh H, Tsuchiya N, Ohyama C, Obara W, Habuchi T. Clinical outcomes of living kidney transplantation from donors aged 70 years and older: a Japanese multicenter study. Sci Rep 18:2694, 2025.
  41. Yanagisawa T, Fukuokaya W, Hatakeyama S, Narita S, Muramoto K, Katsumi K, Takahashi H, Urabe F, Mori K, Tashiro K, Iwatani K, Shimomura T, Habuchi T, Kimura T. Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study. Prostate 85:165-174, 2025.
  42. Zhao H, Liu K, Crisci A, Te Slaa E, Habuchi T, Akand M, Ng CF, Laguna P, Teoh JY, de la Rosette J. Impact of smoking status at diagnosis on oncological outcomes of upper-tract urothelial carcinoma. Ther Adv Urol 28:17562872251352049, 2025.

メニューを開く